Industry News

Laboratory Corporation of America ® Holdings today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, or HSR Act, applicable to the acquisition of Sequenom, Inc. by LabCorp has expired. As previously announced, LabCorp and Savoy Acquisition Corp., its direct wholly owned subsidiary, commenced a tender offer on August 9, 2016, for all of the outstanding shares of common stock of Sequenom, including the..."/>
LabCorp’s Acquisition of Sequenom Clears Antitrust Review
WellCare Health Plans, Inc. announced that effective Oct. 1, 2016, Larry Anderson, senior vice president and chief human resources officer, is leaving the company. Effective Aug. 22, 2016, Anderson is no longer an executive officer, but will remain with WellCare after this time to assist with the transition of his duties and responsibilities. "Larry made significant contributions during his nearly six years with WellCare, including helping to..."/>
WellCare Announces Departure of Chief Human Resources Officer
Tiger X Medical, Inc.. The combined entity, which will change its name to BioCardia following the closing, will trade on the OTC Markets and will focus solely on the business of BioCardia. The combined entity is expected to have $23 million in cash at..."/>
BioCardia, Inc. Signs Merger Agreement with Tiger X Medical, Inc., Secures Funding to Support Further Development of CardiAMP® Cell Therapy System for the Treatment of Heart Failure
Critical Outcome Technologies Inc. a clinical-stage biopharmaceutical company advancing innovative and targeted therapies for the treatment of cancer, announced the official opening of its U.S. headquarters in Boston, Massachusetts. The new office space is located at 127 Main Street, in close proximity to the plethora of life science companies and teaching hospitals in the area. "I am thrilled to be heading up our Boston office and..."/>
Critical Outcome Technologies Announces the Opening of Its U.S. Headquarters
Trimedyne, Inc. today reported its financial results for the quarter and nine-month period ended June 30, 2016.. Revenues for the current quarter were $1,106,000, a decrease of 25% from revenues of $1,482,000 for the prior year's quarter. The decrease in revenues was primarily due to a decrease in sales of Lasers and accessories compared to the prior year period."/>
Trimedyne Reports Its Financial Results for the Quarter and Nine Months Ended June 30, 2016
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced upcoming presentations of data highlighting KRN23 for the treatment of X-linked hypophosphatemia and tumor-induced osteomalacia at the American Society for Bone and Mineral Research 2016 Annual Meeting taking place September 16-19 in Atlanta, Georgia.. Two oral presentations will..."/>
Ultragenyx Announces KRN23 Data Presentations at ASBMR 2016 Annual Meeting
BioTelemetry, Inc., the leading wireless medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, is pleased to announce that it has entered into a strategic partnership with Bloom Technologies, Inc., an early stage digital health company. Under the terms of the agreement, Bloomlife will pay BioTelemetry a percentage of revenue to license their proprietary telemetry technology to..."/>
BioTelemetry, Inc. Agrees to License Proprietary Technology to Bloom Technologies, Inc. for Use in Prenatal Market
Oragenics, a leader in the development of new antibiotics against infectious disease and developing effective treatments for oral mucositis, today announced selection of a second generation lantibiotic, OG716, for treatment of Clostridium difficile and plans to begin Investigational New Drug enabling studies. OG716, a new, orally-active homolog, has exhibited positive results in an animal model for potential treatment of Clostridium difficile."/>
Oragenics Selects New Lantibiotic for Further Development in Clostridium difficile Infections
Henry Schein, Inc., the world's largest provider of health care products and services to office-based dental, animal health and medical practitioners, has again partnered with Integrated Medical Foundation and LUGPA, an association of independent urology group practices, to raise awareness of prostate cancer amid new evidence about the importance of early detection. In recognition of September as National Prostate Cancer Awareness..."/>
Henry Schein Joins IMF and LUGPA to Raise Awareness of Prostate Cancer and the Importance of Early Detection
Misonix, Inc., an international ultrasonic surgical device company that designs, manufactures and markets innovative therapeutic ultrasonic instruments for spine surgery, neurosurgery and other surgical specialties, received a positive reception to the BoneScalpel's ultrasonic technology from more than 60 oral-maxillofacial surgeons attending the Taiwan Association of Maxillofacial Surgeons Forum on Contemporary..."/>
BoneScalpel® Receives Positive Reception From Oral-Maxillofacial Surgeons at Major Taiwanese Conference and Cadaveric Workshop
Teligent, Inc., a New Jersey-based specialty generic pharmaceutical company, today announced that its Estonian subsidiary, Teligent OÜ, has received approval of the Company's New Drug Submission from Health Canada's Therapeutic Products Directorate for Gentamicin Injection USP 40 mg/mL in 2 mL ampoules. This is the first drug approval for Teligent OÜ and will be distributed by Teligent's business in Canada. Based on internal estimates,..."/>
Teligent, Inc. Announces Health Canada Approval Of Gentamicin Injection USP
Vocera Communications, Inc., the leading healthcare communications company, today announced that Vocera executives will present and meet with institutional investors at the Baird 2016 Healthcare Conference on Wednesday, Sept. 7 at 10:50 a.m. ET in New York. The discussion will be available as a webcast, both live and archived, through Vocera’ s website at investors.vocera.com. The replay will be available for 90 days following the live broadcast.."/>
Vocera to Present at Baird 2016 Healthcare Conference
Wellness Center USA, Inc., today announced that it has moved its headquarters to a new location in Hoffman Estates, IL together with its wholly owned subsidiary, National Pain Centers, Inc.. The new facility will provide multiple treatment options for patients with painful conditions, including phototherapy treatments to patients suffering from psoriasis, eczema, vitiligo and more, with its newly deployed Psoria Light, an innovative medical device..."/>
Wellness Center USA, Inc. and National Pain Centers Move to New Hoffman Estates, IL Location
Interleukin Genetics, Inc. a life science company focused on the genetics of chronic inflammation, today announced the publication of the article“ Influence of Obesity on Periodontitis Progression is Conditional on IL-1 Inflammatory Genetic Variation” in the Journal of Periodontology. The article is the result of a scientific collaboration with key researchers at Boston University and strongly supports the value of Interleukin-1 genetics in..."/>
Interleukin-1 Genetic Variations Influence Obesity Effect in Periodontal Disease Progression
Halozyme Therapeutics Inc., Achillion Pharmaceuticals Inc., Aegerion Pharmaceuticals Inc., and Chimerix Inc.."/>
Research Report Coverage on Biotech Stocks -- Halozyme Therapeutics, Achillion Pharma, Aegerion Pharma and Chimerix
Cempra, Inc., a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced that the European Medicines Agency has validated the company’ s marketing authorization application seeking approval of oral capsule and intravenous formulations of solithromycin for the treatment of community-acquired bacterial pneumonia.."/>
Cempra Announces European Medicines Agency Validates MAA for Solithromycin for Treatment of CABP
Stemline Therapeutics, Inc. announced today that the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation to SL-401, a targeted therapy directed to the interleukin-3 receptor, for the treatment of blastic plasmacytoid dendritic cell neoplasm.. The FDA’ s Breakthrough Therapy Designation is intended to expedite the development and review of a drug candidate for serious or life-threatening conditions."/>
Stemline Therapeutics Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for SL-401
Zimmer Biomet Holdings, Inc., a global leader in musculoskeletal healthcare, today announced that its Board of Directors has approved the payment of a quarterly cash dividend to stockholders for the third quarter of 2016.. The cash dividend of $0.24 per share will be paid on or about October 28, 2016 to stockholders of record as of the close of business on September 23, 2016. Future declarations of dividends are subject to approval of the Board of..."/>
Zimmer Biomet Announces Quarterly Dividend for Third Quarter of 2016
Genmab A/S announced today that Janssen Pharmaceutica NV has submitted a variation to the Marketing Authorization to the European Medicines Agency seeking to broaden the existing marketing..."/>
Genmab Announces European Regulatory Submission for Daratumumab in Relapsed Multiple Myeloma
Gilead Sciences reported on Monday the receipt of marketing authorisation from the European Commission for once-daily Truvada to reduce the risk of sexually acquired HIV-1 infection among uninfected adults at high risk. The company said European Commission has approved the once-daily Truvada in combination with safer-sex practices to reduce the risk of sexually acquired HIV-1 infection among uninfected adults at high risk, a strategy..."/>
Gilead awarded European Commission marketing authorisation for Truvada for reducing risk of sexually acquired HIV-1
Veeva Vault enables Daiichi Sankyo to standardize business processes worldwide. PLEASANTON, Calif.& TOKYO---- Veeva Systems today announced that Daiichi Sankyo Company, Limited based in Japan, selected Veeva Vault eTMF, Veeva Vault QualityDocs, and Veeva Vault Submissions to unify content management throughout its research and development operations worldwide. The unique multitenant cloud capabilities of Veeva Vault enable Daiichi Sankyo to easily streamline management..."/>
Daiichi Sankyo Selects Veeva Vault to Streamline Submissions, eTMF, and Quality Management

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Most Popular Sectors in the News
Sectors Articles in the last 7 days
Consumer Discretionary585 Articles
Information Technology559 Articles
Financials466 Articles
Industrials345 Articles
Health Care323 Articles

Sponsored Financial Commentaries

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.